Identification and Validation of Senescence-Related Signature by Combining Single Cell and Bulk Transcriptome Data Analysis to Predict the Prognosis and Identify the Key Gene CAV1 in Pancreatic Cancer

被引:0
作者
Chen, Liang [1 ]
Ying, Xiaomei [2 ]
Wang, Haohao [1 ]
Xie, Jiaheng [3 ]
Tang, Qikai [4 ]
Liu, Wen [1 ]
机构
[1] Jiaxing Univ, Hosp Jiaxing 1, Affiliated Hosp, Convers therapy Ctr Hepatobiliary & Pancreat Tumor, Jiaxing, Zhejiang, Peoples R China
[2] Anhui Med Univ, Suzhou Hosp, Dept Gen Surg, Suzhou, Anhui, Peoples R China
[3] Cent South Univ, Xiangya Hosp, Dept Plast & Cosmet Surg, Changsha 410008, Hunan, Peoples R China
[4] Nanjing Univ, Nanjing Jinling Hosp, Affiliated Hosp, Med Sch, Nanjing, Jiangsu, Peoples R China
关键词
pancreatic cancer; cellular senescence; prognosis; biomarker; immunotherapy;
D O I
10.2147/JIR.S489985
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The role of cellular senescence in the tumor microenvironment of pancreatic cancer (PC) remains unclear, particularly regarding its impact on prognosis and immunotherapy outcomes. Methods: We utilized single-cell sequencing datasets (GSE155698 and GSE154778) for pancreatic cancer from the Gene Expression Omnibus (GEO) database and bulk RNA-seq data from the University of California, Santa Cruz (UCSC) and International Cancer Genome Consortium (ICGC) repositories, creating three patient cohorts: The Cancer Genome Atlas (TCGA) cohort, PAAD-AU cohort, and PAAD-CA cohort. Dimensionality reduction cluster analysis processed the single-cell data, while weighted gene coexpression network analysis (WGCNA) and differential expression gene analysis were applied to bulk RNA-seq data. Prognostic models were developed using Cox proportional hazards (COX) and least absolute shrinkage and selection operator (LASSO) regression, with validation through survival analysis, decision curve analysis, and principal component analysis (PCA). Tumor mutation data were analyzed using the "maftools" package, and the immune microenvironment was assessed with TIMER2 data. Results: We developed a senescence-related (SENR) six-gene prognostic signature for PC, which stratifies patients by risk, with highrisk groups showing poorer prognoses. This model also offers predictive insights into tumor mutations and immune microenvironment characteristics. Caveolin-1 (CAV1) emerged as a significant prognostic biomarker, with functional validation showing its role in promoting cancer cell proliferation and migration, highlighting its potential as a therapeutic target. Conclusion: This study provides a novel senescence-related prognostic tool for PC, enhancing patient stratification for prognosis and immunotherapy, and identifies CAV1 as a key gene with clinical significance for targeted interventions.
引用
收藏
页码:9391 / 9406
页数:16
相关论文
共 32 条
[1]   Hereditary pancreatic cancer [J].
Abe, Kodai ;
Kitago, Minoru ;
Kitagawa, Yuko ;
Hirasawa, Akira .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (10) :1784-1792
[2]   Blood biomarkers for differential diagnosis and early detection of pancreatic cancer [J].
Al-Shaheri, Fawaz N. ;
Alhamdani, Mohamed S. S. ;
Bauer, Andrea S. ;
Giese, Nathalia ;
Buechler, Markus W. ;
Hackert, Thilo ;
Hoheisel, Joerg D. .
CANCER TREATMENT REVIEWS, 2021, 96
[3]   Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis [J].
Cai, Jie ;
Chen, Hongda ;
Lu, Ming ;
Zhang, Yuhan ;
Lu, Bin ;
You, Lei ;
Zhang, Taiping ;
Dai, Min ;
Zhao, Yupei .
CANCER LETTERS, 2021, 520 :1-11
[4]   CELLULAR SENESCENCE: AGING, CANCER, AND INJURY [J].
Calcinotto, Arianna ;
Kohli, Jaskaren ;
Zagato, Elena ;
Pellegrini, Laura ;
Demaria, Marco ;
Alimonti, Andrea .
PHYSIOLOGICAL REVIEWS, 2019, 99 (02) :1047-1078
[5]   A necroptosis related prognostic model of pancreatic cancer based on single cell sequencing analysis and transcriptome analysis [J].
Chen, Liang ;
Zhang, Xueming ;
Zhang, Qixiang ;
Zhang, Tao ;
Xie, Jiaheng ;
Wei, Wei ;
Wang, Ying ;
Yu, Hongzhu ;
Zhou, Hongkun .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[6]   Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies [J].
Chiorean, Elena Gabriela ;
Coveler, Andrew L. .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 :3529-3545
[7]   Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients [J].
Chung, Vincent ;
Sun, Virginia ;
Ruel, Nora ;
Smith, Thomas J. ;
Ferrell, Betty R. .
JOURNAL OF PALLIATIVE MEDICINE, 2022, 25 (05) :720-727
[8]   Caveolin-1: A Promising Therapeutic Target for Diverse Diseases [J].
Gokani, Shivani ;
Bhatt, Lokesh Kumar .
CURRENT MOLECULAR PHARMACOLOGY, 2022, 15 (05) :701-715
[9]   Pancreatic cancer: Advances and challenges [J].
Halbrook, Christopher J. ;
Lyssiotis, Costas A. ;
di Magliano, Marina Pasca ;
Maitra, Anirban .
CELL, 2023, 186 (08) :1729-1754
[10]   Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication [J].
Hou, Jun ;
Li, XueTao ;
Xie, Ke-Ping .
MOLECULAR CANCER, 2021, 20 (01)